Press release content from Accesswire. The AP news staff was not involved in its creation.
Core One Labs to Rescind Share Exchange with Plant-Based Investment Corp.
April 15, 2021 GMT
VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the Company or Core One ) announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth .
VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the Company or Core One ) announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth .
Core One Labs to Rescind Share Exchange with Plant-Based Investment Corp
digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.
Core One Labs Vocan Expands Product Commercialization Team
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Core One Labs Inc.: Core One Labs Vocan Expands Product Commercialization Team
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the
Company or
Core One ) is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (
Vocan ) has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs.
Dr. Matthews will oversee research and development, as well as the commercialization of Vocan s new product offerings, including the navigation of regulatory processes involved during transition from laboratory to market.
Dr. Matthews brings extensive experience as both a scientist and a regulatory affairs expert, and her knowledge of, and aptitude in, navigating regulatory processes and eligibility requirements for scientific products will effectively mitigate timelines in getting Vocan s proprietary alternative medicinal products to market. Dr. Matthews is a microbiologist with over
MindMed (OTCQB:MMEDF) released its full-year 2020 financial results.
The company posted a net and comprehensive loss of $35.1 million for the year ended Dec. 31, 2020. Its total assets at the end of the reporting period were $85.6 million, counting $80.1 million in cash.
The company used $24.2 million of net cash in operating activities in 2020.
Its cash balance as of Tuesday last week hovered at $161 million. The company plans to use the money to improve its portfolio and develop its technology sector.
On Monday, MindMed also revealed the results of a study on personalized MDMA dosing, conducted in conjunction with the Liechti Lab at the University Hospital Basel, in Switzerland.